Chimeric anti-VEGF-D antibodies and humanized anti-VEGF-D...

Details Chimeric anti-VEGF-D antibodies and humanized anti-VEGF-D... Chimeric anti-VEGF-D antibodies and humanized anti-VEGF-D...

2008-06-30

2010-12-07

Huynh, Phuong (Department: 1644)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Structurally-modified antibody, immunoglobulin, or fragment...

C424S141100, C424S145100

Reexamination Certificate

active

07846437

ABSTRACT:
The present invention relates to materials and methods for modulating angiogenesis and lymphangiogenesis. The compositions of the invention provide chimeric and/or humanized VEGF-D antibody substances, antibodies, polypeptides and fragments thereof useful for modulating angiogenesis and lymphangiogenesis in a subject.

REFERENCES:
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5607918 (1997-03-01), Eriksson et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5840693 (1998-11-01), Eriksson et al.
patent: 5919899 (1999-07-01), Persico et al.
patent: 5928939 (1999-07-01), Eriksson et al.
patent: 6130071 (2000-10-01), Alitalo et al.
patent: 6221839 (2001-04-01), Alitalo et al.
patent: 6235713 (2001-05-01), Achen et al.
patent: 6245530 (2001-06-01), Alitalo et al.
patent: 6331301 (2001-12-01), Eriksson et al.
patent: 6361946 (2002-03-01), Alitalo et al.
patent: 6383484 (2002-05-01), Achen et al.
patent: 6403088 (2002-06-01), Alitalo et al.
patent: 6645933 (2003-11-01), Alitalo et al.
patent: 7097986 (2006-08-01), Achen et al.
patent: 7122654 (2006-10-01), Achen et al.
patent: 7410639 (2008-08-01), Achen et al.
patent: 7534572 (2009-05-01), Achen et al.
patent: 7662932 (2010-02-01), Achen et al.
patent: 2003/0113870 (2003-06-01), Ferrara et al.
patent: 2005/0282233 (2005-12-01), Eriksson et al.
patent: 2006/0030000 (2006-02-01), Alitalo et al.
patent: 9519928.7 (1995-09-01), None
patent: 9612368.2 (1996-06-01), None
patent: 0935001 (1999-08-01), None
patent: 8-185216 (1996-07-01), None
patent: WO-93/11236 (1993-06-01), None
patent: WO-96/11269 (1996-04-01), None
patent: WO-96/26736 (1996-09-01), None
patent: WO-97/05250 (1997-02-01), None
patent: WO-97/12972 (1997-04-01), None
patent: WO-98/02543 (1998-01-01), None
patent: WO-98/07832 (1998-02-01), None
patent: WO-98/33917 (1998-08-01), None
patent: WO00/18212 (2000-04-01), None
patent: WO-00/21560 (2000-04-01), None
patent: WO-00/25805 (2000-05-01), None
patent: WO-00/27879 (2000-05-01), None
patent: WO00/37025 (2000-06-01), None
patent: WO-02/060950 (2002-08-01), None
De Pascalis et al, Journal of Immunology 169: 3076-3084, 2002.
Vajdos et al, J. Mol. Biol. 320: 415-428, 2002.
Holm et al, Mol. Immunol. 44: 1075-1084, 2007.
Chen, J. Mol. Biol. 293: 865-881, 1999.
U.S. Appl. No. 11/692,774, Achen et al.
U.S. Appl. No. 11/692,753, Achen et al.
U.S. Appl. No. 11/772,089, Achen et al.
Achen et al., “Monoclonal antibodies to vascular endothelial growth factor-D block its interactions with both VEGF receptor-2 and VEGF receptor-3,”Eur. J. Biochem.,267:2505-2515 (2000).
Achen et al., “Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (F1k1) and VEGF receptor 3 (Flt4),”Proc. Natl. Acad. Sci. USA,95:548-553 (1998).
Barrios et al., “Length of the antibody heavy chain complementarily determining region 3 as a specificity-determining factor,”J. Mol. Recognition,17:332-8 (2004).
Breiteneder-Geleff et al., “Angiosarcomas experss mixed endothelial phenotypes of blood and lymphatic capillaries,”Am. J. Pathol.,154:385-394 (1999).
Cao et al., “Vascular endothelial growth factor C induces angiogenesis in vivo,”Proc. Natl. Acad. Sci. USA,95:14389-14394, 1998.
Chomczynski et al., “Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction,”Anal. Biochem.,162:156-159 (1987).
Cobleigh et al., “A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer,”Seminars in Oncology,30(Suppl 16):117-124 (2003).
Dumont et al., “Cardiovascular failure in mouse embryos deficient in VEGF receptor-3,”Science,282:946-949 (1998).
Dumont et al., “Vascularization of the mouse embryo: a study of flk-1, tek, tie, and vascular endothelial growth factor expression during development,”Developmental Dynamics,203:80-92 (1995).
Ferrara, “Molecular and biological properties of vascular endothelial growth factor,”J. Mol. Med.,77:527-543 (1999).
Folkman et al., “Angiogenesis,”J. Biol. Chem.,267:10931-10934 (1992).
Fong et al., “Regulation of flt-1 expression during mouse embryogenesis suggests a role in the establishment of vascular endothelium,”Developmental Dynamics,207:1-10 (1996).
Fong et al., “Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium,”Nature,376:66-70 (1995).
Hiratsuka et al., “Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice,”Proc. Natl. Acad. Sci. USA,95:9349-9354 (1998).
Jeltsch et al., “Hyperplasia of lymphatic vessels in VEGF-C transgenic mice,”Science,276:1423-1425 (1997).
Jones et al., “Replacing the complementarity-determining regions in a human antibody with those from a mouse,”Nature,321:522-525 (1986).
Joukov et al., “A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGR-3) and KDR (VEGFR-2) receptor tyrosine kinases,”The EMBO J.,15:290-298 (1996).
Jussila et al., “Lymphatic endothelium and kaposi's sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3,”Cancer Research,58:1955-1604 (1998).
Kaipainen et al., “Enhanced expression of the tie receptor tyrosine kinase messenger RNA in the vascular endothelium of metastatic melanomas,”Cancer Research,54:6571-6577 (1994).
Kaipainen et al., “Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development,”Proc. Natl. Acad. Sci. USA,9:3566-3570 (1995).
Kaipainen et al., “The related FLT4,FLT1, and KDR receptor tyrosine kinases show distinct expression patterns in human fetal endothelial cells,”J. Exp. Med.,178:2077-2088 (1993).
Karpanen et al., “Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth,”Cancer Research,61:1786-1790 (2001).
Kobrin et al., “A V region mutation in a phosphocholine-binding monoclonal antibody results in loss of antigen binding,”J. Immunol.,146:2017-20 (1991).
Kortt et al., “Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting,”Biomol. Eng..,18:95-108 (2001).
Kozak, “An analysis of 5'-noncoding sequences from 699 vertebrate messenger RNAs,”Nucleic Acids Research,15:8125-8148 (1987).
Kyte et al., “A simple method for displaying the hydropathic character ofa protein,”J. Mol. Biol.,157:105-132 (1982).
Layton et al., “Neutralising antibodies to the granulocyte colony-stimulating factor receptor recognise both teh immunoglobulin-like domain and the cytokine receptor homologous domain,”Growth Factors,14:117-130 (1997).
MacCallum et al., “Antibody-antigen interactions: contact analysis and binding site topography,”J. Mol. Biol.,262:732-45 (1996).
Marconcini et el., “C-fos-indused growth factor/vascular endothelial growth factor D induces angiogenesis in vivo and in vitro,”Proc. Natl. Acad. Sci. USA,96:9671-9676 (1999).
Meissner et al., “Transient gene expression: recombinant protein production with suspension-adapted HEK293-EBNA cells,”Biotechnol. Bioeng.,75:197-203 (2001).
Meyer et al., “A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases,”The Embo J.,18:363-374 (1999).
Muller et al., “The crystal structure of vascular endothelial growth factor (VEGF) refined to 1.93 A resolution: multiple copy flexibility and receptor binding,”Structure,5:1325-1338 (1997).
Neufeld et al., “Vascular endothelial growth factor (VEGF) and its receptors,”FASEB J.,13:9-22 (1999).
Oelrichs et al., “NYK/FLK-1: a putative receptor

Affiliated with

Also associated with

Rating

Chimeric anti-VEGF-D antibodies and humanized anti-VEGF-D... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Chimeric anti-VEGF-D antibodies and humanized anti-VEGF-D..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chimeric anti-VEGF-D antibodies and humanized anti-VEGF-D... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4174601